Singapore, July 10 -- Japan's JCR Pharmaceuticals Co. has entered into a license agreement with Alexion, AstraZeneca Rare Disease, for JCR's new, proprietary JUST-AAV capsids to develop genomic medicines.

JUST-AAV encompasses a range of vector types optimized for various target tissues-including liver-sparing, muscle-targeting, and brain-targeting variants-to expand the potential of AAV-based gene therapy.

Under the terms of the agreement, Alexion may use the licensed capsids, which are part of the JUST-AAV platform, in up to five of Alexion's genomic medicines programmes.

JCR will receive an upfront payment from Alexion. JCR is eligible to receive milestone payments of up to $225 million related to research and development, and up to ...